Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus:A mini review  

作　　者：Kay Choong See 

机构地区：[1]Department of Medicine,National University Hospital,Singapore 119228,Singapore

出　　处：《World Journal of Diabetes》2023年第8期1202-1211,共10页世界糖尿病杂志（英文版）（电子版）

摘　　要：Inhaled corticosteroids(ICS)and intranasal corticosteroids(INS)are the mainstays of treatment for chronic respiratory diseases like asthma,chronic obstructive pulmonary disease,and allergic rhinosinusitis.In addition,these localized forms of steroid therapy are generally considered to have fewer systemic side effects compared to long-term oral corticosteroids.However,concern and controversy remain over the impact of ICS and INS on the incidence and control of diabetes mellitus(DM).Given the widespread use of ICS and INS,even small individual effects on DM could lead to large consequences for the global population.Multiple large observational studies suggest that high dose ICS is associated with increased incident DM and worsened DM control,though the contribution of other risk factors is less certain.In addition,only two studies were done to investigate the association of INS and DM,with both studies demonstrating a short-term association of INS use with hyperglycemia.While more research evaluating the risk of ICS/INS for DM-related adverse events is needed,high doses of ICS/INS should be avoided when possible.The following strategies for ICS/INS dose minimization can be considered:Use of non-pharmacological measures(trigger avoidance,smoking cessation,vaccination to avoid infection),control of comorbid conditions,use of non-ICS-containing medications,intermittent rather than regular ICS dosing,and appropriate de-escalation of high ICS doses.

关 键 词：BECLOMETHASONE BUDESONIDE FLUTICASONE GLUCOCORTICOIDS Glucose HYPERGLYCEMIA 

分 类 号：R587.1[医药卫生—内分泌]